Vaxcyte (NASDAQ:PCVX – Get Rating) announced its earnings results on Monday. The company reported ($0.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.05), MarketWatch Earnings reports.
NASDAQ PCVX traded up $0.04 during trading on Tuesday, reaching $21.45. The company’s stock had a trading volume of 27,829 shares, compared to its average volume of 306,998. The company has a market capitalization of $1.25 billion, a PE ratio of -11.21 and a beta of 0.41. The stock has a fifty day moving average of $24.62. Vaxcyte has a one year low of $15.51 and a one year high of $27.44.
In related news, COO Jim Wassil sold 10,000 shares of the firm’s stock in a transaction dated Thursday, February 24th. The stock was sold at an average price of $22.00, for a total transaction of $220,000.00. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Grant Pickering sold 14,288 shares of the firm’s stock in a transaction dated Monday, March 21st. The shares were sold at an average price of $24.94, for a total value of $356,342.72. The disclosure for this sale can be found here. Over the last three months, insiders have sold 69,076 shares of company stock worth $1,687,682. 21.70% of the stock is currently owned by insiders.
A number of brokerages have weighed in on PCVX. Zacks Investment Research lowered Vaxcyte from a “buy” rating to a “hold” rating in a research note on Wednesday, March 2nd. Needham & Company LLC restated a “buy” rating and issued a $52.00 target price on shares of Vaxcyte in a research note on Thursday, February 24th.
About Vaxcyte (Get Rating)
Vaxcyte, Inc, a preclinical-stage biotechnology vaccine company, develops novel vaccines to prevent or treat infectious diseases worldwide. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting Porphyromonas gingivalis.
- Get a free copy of the StockNews.com research report on Vaxcyte (PCVX)
- If PetMeds Is A Good Buy There Will Be A Better Signal
- Insiders Buy Occidental Petroleum Ahead Of Q1 Earnings
- High-Yield Deep-Value LCI Industries Exceeds All Expectations
- Shopify (NYSE: SHOP) Approaches Key Support Level
- The Low In Lordstown Motors May Not Be The Last
Receive News & Ratings for Vaxcyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxcyte and related companies with MarketBeat.com's FREE daily email newsletter.